American Banking and Market News logo

The Latest Headlines at American Banking and Market News

Image about Aurinia Pharmaceuticals (TSE:AUP) Stock Passes Below 50-Day Moving Average of $16.76

Aurinia Pharmaceuticals (TSE:AUP) Stock Passes Below 50-Day Moving Average of $16.76

Aurinia Pharmaceuticals Inc. (TSE:AUP – Get Free Report) (NASDAQ:AUPH)’s share price crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of C$16.76 and traded as low... More of this article »
Image about Zuora’s (ZUO) Buy Rating Reaffirmed at Needham & Company LLC

Zuora’s (ZUO) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Zuora (NYSE:ZUO – Free Report) in a research report report published on Tuesday morning, Benzinga reports. They currently have a $15.00 price target on the stock. Several... More of this article »
Image about Zoetis (NYSE:ZTS) Price Target Cut to $180.00 by Analysts at Stifel Nicolaus

Zoetis (NYSE:ZTS) Price Target Cut to $180.00 by Analysts at Stifel Nicolaus

Zoetis (NYSE:ZTS – Free Report) had its target price trimmed by Stifel Nicolaus from $195.00 to $180.00 in a research note published on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock. Other analysts... More of this article »
Image about Five Star Bancorp (NASDAQ:FSBC) Receives “Buy” Rating from DA Davidson

Five Star Bancorp (NASDAQ:FSBC) Receives “Buy” Rating from DA Davidson

DA Davidson reaffirmed their buy rating on shares of Five Star Bancorp (NASDAQ:FSBC – Free Report) in a research note released on Tuesday, Benzinga reports. DA Davidson currently has a $29.00 price objective on the stock. Separately,... More of this article »
Image about Exxon Mobil (NYSE:XOM) Price Target Increased to $120.00 by Analysts at HSBC

Exxon Mobil (NYSE:XOM) Price Target Increased to $120.00 by Analysts at HSBC

Exxon Mobil (NYSE:XOM – Free Report) had its target price hoisted by HSBC from $111.00 to $120.00 in a report published on Tuesday morning, Benzinga reports. The brokerage currently has a hold rating on the oil and gas company’s... More of this article »
Image about Flexsteel Industries (NASDAQ:FLXS) Upgraded to “Buy” by StockNews.com

Flexsteel Industries (NASDAQ:FLXS) Upgraded to “Buy” by StockNews.com

StockNews.com upgraded shares of Flexsteel Industries (NASDAQ:FLXS – Free Report) from a hold rating to a buy rating in a report released on Tuesday. Separately, TheStreet raised shares of Flexsteel Industries from a c rating... More of this article »
Image about Booking (NASDAQ:BKNG) Lowered to “Hold” at StockNews.com

Booking (NASDAQ:BKNG) Lowered to “Hold” at StockNews.com

StockNews.com downgraded shares of Booking (NASDAQ:BKNG – Free Report) from a buy rating to a hold rating in a research report released on Tuesday. A number of other brokerages have also issued reports on BKNG. B. Riley started... More of this article »
Image about Avid Bioservices (NASDAQ:CDMO) Price Target Raised to $8.00 at Royal Bank of Canada

Avid Bioservices (NASDAQ:CDMO) Price Target Raised to $8.00 at Royal Bank of Canada

Avid Bioservices (NASDAQ:CDMO – Free Report) had its price target raised by Royal Bank of Canada from $7.00 to $8.00 in a report issued on Tuesday, Benzinga reports. They currently have an outperform rating on the biopharmaceutical... More of this article »
Image about HCA Healthcare (NYSE:HCA) Price Target Cut to $360.00 by Analysts at TD Cowen

HCA Healthcare (NYSE:HCA) Price Target Cut to $360.00 by Analysts at TD Cowen

HCA Healthcare (NYSE:HCA – Free Report) had its price target trimmed by TD Cowen from $371.00 to $360.00 in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock. Other... More of this article »
Image about Deciphera Pharmaceuticals’ (DCPH) Market Perform Rating Reaffirmed at JMP Securities

Deciphera Pharmaceuticals’ (DCPH) Market Perform Rating Reaffirmed at JMP Securities

JMP Securities reaffirmed their market perform rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a research note released on Tuesday morning, Benzinga reports. Several other brokerages also recently... More of this article »
Image about Bank of Marin Bancorp (NASDAQ:BMRC) Given New $15.00 Price Target at DA Davidson

Bank of Marin Bancorp (NASDAQ:BMRC) Given New $15.00 Price Target at DA Davidson

Bank of Marin Bancorp (NASDAQ:BMRC – Free Report) had its price objective cut by DA Davidson from $17.00 to $15.00 in a report released on Tuesday morning, Benzinga reports. They currently have a neutral rating on the bank’s... More of this article »
Image about Bank of Marin Bancorp (NASDAQ:BMRC) Price Target Lowered to $16.00 at Stephens

Bank of Marin Bancorp (NASDAQ:BMRC) Price Target Lowered to $16.00 at Stephens

Bank of Marin Bancorp (NASDAQ:BMRC – Free Report) had its target price lowered by Stephens from $19.00 to $16.00 in a report issued on Tuesday morning, Benzinga reports. Stephens currently has an equal weight rating on the bank’s... More of this article »
Image about Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Below 50-Day Moving Average of $1.83

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Below 50-Day Moving Average of $1.83

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $1.83 and traded as low as $1.53. Corvus Pharmaceuticals... More of this article »
Image about Alliance Resource Partners (NASDAQ:ARLP) Upgraded by StockNews.com to “Strong-Buy”

Alliance Resource Partners (NASDAQ:ARLP) Upgraded by StockNews.com to “Strong-Buy”

StockNews.com upgraded shares of Alliance Resource Partners (NASDAQ:ARLP – Free Report) from a buy rating to a strong-buy rating in a research report sent to investors on Tuesday morning. Separately, Benchmark reiterated a buy... More of this article »
Image about Deciphera Pharmaceuticals (NASDAQ:DCPH) Receives “Neutral” Rating from Guggenheim

Deciphera Pharmaceuticals (NASDAQ:DCPH) Receives “Neutral” Rating from Guggenheim

Guggenheim reiterated their neutral rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH – Free Report) in a research report released on Tuesday, Benzinga reports. Several other equities research analysts also recently... More of this article »